Roles of F-box proteins in cancer

Nature Reviews Cancer

Volumn 14, Issue 4, 2014, Pages 233-247

  Wang, Zhiwei ^a,b   Liu, Pengda ^a   Inuzuka, Hiroyuki ^a   Wei, Wenyi ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATROGIN 1; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN 1; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN 2; F BOX AND LEUCINE RICH REPEAT PROTEIN 10; F BOX AND LEUCINE RICH REPEAT PROTEIN 2; F BOX AND LEUCINE RICH REPEAT PROTEIN 20; F BOX AND LEUCINE RICH REPEAT PROTEIN 21; F BOX AND LEUCINE RICH REPEAT PROTEIN 3; F BOX AND LEUCINE RICH REPEAT PROTEIN 5; F BOX AND WD REPEAT DOMAIN CONTAINING 7 PROTEIN; F BOX AND WD REPEAT DOMAIN CONTAINING 8 PROTEIN; F BOX ONLY PROTEIN 1; F BOX ONLY PROTEIN 10; F BOX ONLY PROTEIN 11; F BOX ONLY PROTEIN 15; F BOX ONLY PROTEIN 18; F BOX ONLY PROTEIN 2; F BOX ONLY PROTEIN 31; F BOX ONLY PROTEIN 4; F BOX ONLY PROTEIN 45; F BOX ONLY PROTEIN 5; F BOX ONLY PROTEIN 7; F BOX ONLY PROTEIN 9; F BOX PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG;

CANCER INHIBITION; CARCINOGENESIS; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; F-BOX PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOGENES; PROTEOLYSIS; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

EID: 84897085768     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3700     Document Type: Review

References (198)

1. Li, W. et al. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS ONE 3, e1487 (2008).
2. Deshaies, R. J. & Joazeiro, C. A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78, 399-434 (2009).
3. Petroski, M. D. & Deshaies, R. J. Function and regulation of cullin-RING ubiquitin ligases. Nature Rev. Mol. Cell Biol. 6, 9-20 (2005)
4. Frescas, D. & Pagano, M. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nature Rev. Cancer 8, 438-449 (2008).
5. Bai, C. et al. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86, 263-274 (1996).
6. Nakayama, K. I. & Nakayama, K. Ubiquitin ligases: cell-cycle control and cancer. Nature Rev. Cancer 6, 369-381 (2006).
7. Watanabe, N. et al. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFβ-TrCP. Proc. Natl Acad. Sci. USA 101, 4419-4424 (2004).
8. Peters, J. M. The anaphase promoting complex/cyclosome: a machine designed to destroy. Nature Rev. Mol. Cell Biol. 7, 644-656 (2006).
9. Harper, J. W., Burton, J. L. & Solomon, M. J. The anaphase-promoting complex: it's not just for mitosis any more. Genes Dev. 16, 2179-2206 (2002).
10. D'Angiolella, V. et al. SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature 466, 138-142 (2010).
11. Duan, S. et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 481, 90-93 (2012).
12. Rye, M. S. et al. FBXO11, a regulator of the TGFβ pathway, is associated with severe otitis media in Western Australian children. Genes Immun. 12, 352-359 (2011).
13. Santra, M. K., Wajapeyee, N. & Green, M. R. F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 459, 722-725 (2009).
14. Skaar, J. R., Pagan, J. K. & Pagano, M. Mechanisms and function of substrate recruitment by F-box proteins. Nature Rev. Mol. Cell Biol. 14, 369-381 (2013).
15. Nash, P. et al. Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature 414, 514-521 (2001).
16. Orlicky, S., Tang, X., Willems, A., Tyers, M. & Sicheri, F. Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell 112, 243-256 (2003).
17. Yoshida, Y. et al. Fbs2 is a new member of the E3 ubiquitin ligase family that recognizes sugar chains. J. Biol. Chem. 278, 43877-43884 (2003).
18. Yoshida, Y. et al. E3 ubiquitin ligase that recognizes sugar chains. Nature 418, 438-442 (2002).
19. D'Angiolella, V. et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell 149, 1023-1034 (2012).
20. Kuchay, S. et al. FBXL2-And PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade. Nature Cell Biol. 15, 472-480 (2013).
21. Abbas, T. et al. CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration. Mol. Cell 49, 1147-1158 (2013).
22. Fbxo11 ubiquitin ligase. Mol. Cell 49, 1159-1166 (2013).
23. Lee, J. M. et al. EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol. Cell 48, 572-586 (2012).
24. Nakayama, K. I. & Nakayama, K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin. Cell Dev. Biol. 16, 323-333 (2005).
25. Fbw7 complex in development and transformation. Oncogene 29, 4865-4873 (2010).
26. Welcker, M. & Clurman, B. E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nature Rev. Cancer 8, 83-93 (2008).
27. Tsunematsu, R. et al. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J. Biol. Chem. 279, 9417-9423 (2004).
28. Tetzlaff, M. T. et al. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc. Natl Acad. Sci. USA 101, 3338-3345 (2004).
29. Akhoondi, S. et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 67, 9006-9012 (2007).
30. Onoyama, I. et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J. Exp. Med. 204, 2875-2888 (2007).
31. Matsuoka, S. et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev. 22, 986-991 (2008).
32. Thompson, B. J. et al. Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J. Exp. Med. 205, 1395-1408 (2008).
33. Maser, R. S. et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447, 966-971 (2007).
34. King, B. et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 153, 1552-1566 (2013).
35. Sancho, R. et al. F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. Gastroenterology 139, 929-941 (2010).
36. Davis, H., Lewis, A., Behrens, A. & Tomlinson, I. Investigation of the atypical FBXW7 mutation spectrum in human tumours by conditional expression of a heterozygous propellor tip missense allele in the mouse intestines. Gut http://dx.doi.org/10.1136/gutjnl-2013-304719 (2013)
37. Welcker, M. & Clurman, B. E. Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell Div. 2, 7 (2007).
38. Tang, X. et al. Suprafacial orientation of the SCFCdc4 dimer accommodates multiple geometries for substrate ubiquitination. Cell 129, 1165-1176 (2007).
39. Onoyama, I. et al. Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver. J. Clin. Invest. 121, 342-354 (2011).
40. Mao, J. H. et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432, 775-779 (2004).
41. Akhoondi, S. et al. Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res. 12, R105 (2010).
42. Matsumoto, A. et al. Fbxw7β resides in the endoplasmic reticulum membrane and protects cells from oxidative stress. Cancer Sci. 102, 749-755 (2011).
43. Yokobori, T. et al. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res. 69, 3788-3794 (2009).
44. Koh, M. S., Ittmann, M., Kadmon, D., Thompson, T. C. & Leach, F. S. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol. Ther. 5, 78-83 (2006).
45. Mann, K. M. et al. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc. Natl Acad. Sci. USA 109, 5934-5941 (2012).
46. Hardisty-Hughes, R. E. et al. A mutation in the F-box gene, Fbxo11, causes otitis media in the Jeff mouse. Hum. Mol. Genet. 15, 3273-3279 (2006).
47. Tsunematsu, R. et al. Fbxw8 is essential for Cul1-Cul7 complex formation and for placental development. Mol. Cell. Biol. 26, 6157-6169 (2006).
48. Tsutsumi, T., Kuwabara, H., Arai, T., Xiao, Y. & Decaprio, J. A. Disruption of the Fbxw8 gene results in pre-And postnatal growth retardation in mice. Mol. Cell. Biol. 28, 743-751 (2008).
49. Kim, S. J. et al. mTOR complex 2 regulates proper turnover of insulin receptor substrate-1 via the ubiquitin ligase subunit Fbw8. Mol. Cell 48, 875-887 (2012).
50. Okabe, H. et al. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS ONE 1, e128 (2006).
51. Lin, P. et al. Fbxw8 is involved in the proliferation of human choriocarcinoma JEG-3 cells. Mol. Biol. Rep. 38, 1741-1747 (2011).
52. Siepka, S. M. et al. Circadian mutant Overtime reveals F-box protein FBXL3 regulation of cryptochrome and period gene expression. Cell 129, 1011-1023 (2007).
53. Godinho, S. I. et al. The after-hours mutant reveals a role for Fbxl3 in determining mammalian circadian period. Science 316, 897-900 (2007).
54. Busino, L. et al. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science 316, 900-904 (2007).
55. Yoo, S. H. et al. Competing E3 ubiquitin ligases govern circadian periodicity by degradation of CRY in nucleus and cytoplasm. Cell 152, 1091-1105 (2013).
56. FBXL3 ubiquitin ligase targets cryptochromes at their cofactor pocket. Nature 496, 64-68 (2013).
57. Kelleher, F. C., Rao, A. & Maguire, A. Circadian molecular clocks and cancer. Cancer Lett. 342, 9-18 (2014).
58. Lahti, T., Merikanto, I. & Partonen, T. Circadian clock disruptions and the risk of cancer. Ann. Med. 44, 847-853 (2012).
59. Tetzlaff, M. T. et al. Cyclin F disruption compromises placental development and affects normal cell cycle execution. Mol. Cell. Biol. 24, 2487-2498 (2004).
60. Fu, J. et al. Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. Cancer Sci. 104, 508-515 (2013).
61. Vaites, L. P. et al. The Fbx4 tumor suppressor regulates cyclin D1 accumulation and prevents neoplastic transformation. Mol. Cell. Biol. 31, 4513-4523 (2011).
62. Kanie, T. et al. Genetic reevaluation of the role of F-box proteins in cyclin D1 degradation. Mol. Cell. Biol. 32, 590-605 (2012).
63. FBX4-αB crystallin complex. Mol. Cell 24, 355-366 (2006).
64. Fbx4 ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell 14, 68-78 (2008).
65. Chiorazzi, M. et al. Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma. Proc. Natl Acad. Sci. USA 110, 3943-3948 (2013).
66. Samuelson, D. J. et al. Rat Mcs5a is a compound quantitative trait locus with orthologous human loci that associate with breast cancer risk. Proc. Natl Acad. Sci. USA 104, 6299-6304 (2007).
67. Smits, B. M. et al. An insulator loop resides between the synthetically interacting elements of the human/rat conserved breast cancer susceptibility locus MCS5A/Mcs5a. Nucleic Acids Res. 40, 132-147 (2012).
68. Xu, X. et al. Human MCS5A1 candidate breast cancer susceptibility gene FBXO10 is induced by cellular stress and correlated with lens epithelium-derived growth factor (LEDGF). Mol. Carcinog. http://dx.doi. org/10.1002/mc.21977 (2012).
69. Jeong, Y. T., Cermak, L., Guijarro, M. V., Hernando, E. & Pagano, M. FBH1 protects melanocytes from transformation and is deregulated in melanomas. Cell Cycle 12, 1128-1132 (2013).
70. Kumar, R. et al. FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex. Cancer Res. 65, 11304-11313 (2005).
71. Huang, H. L., Zheng, W. L., Zhao, R., Zhang, B. & Ma, W. L. FBXO31 is down-regulated and may function as a tumor suppressor in hepatocellular carcinoma. Oncol. Rep. 24, 715-720 (2010).
72. Carrano, A. C., Eytan, E., Hershko, A. & Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Biol. 1, 193-199 (1999).
73. Sutterluty, H. et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nature Cell Biol. 1, 207-214 (1999).
74. Skp2 complex through phosphorylated Thr187 in p27. Curr. Biol. 9, 661-664 (1999).
75. Yu, Z. K., Gervais, J. L. & Zhang, H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc. Natl Acad. Sci. USA 95, 11324-11329 (1998).
76. Shim, E. H. et al. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res. 63, 1583-1588 (2003).
77. Latres, E. et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl Acad. Sci. USA 98, 2515-2520 (2001).
78. Umanskaya, K. et al. Skp2B stimulates mammary gland development by inhibiting REA, the repressor of the estrogen receptor. Mol. Cell. Biol. 27, 7615-7622 (2007).
79. Lin, H. K. et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464, 374-379 (2010).
80. Chan, C. H. et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 149, 1098-1111 (2012).
81. Zhao, H. et al. Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors. Cancer Cell 24, 645-659 (2013).
82. +/- mice. Nature Genet. 42, 83-88 (2010).
83. Kip1 accumulation. Am. J. Pathol. 182, 1854-1864 (2013).
84. Seki, R. et al. Prognostic significance of S-phase kinase-Associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. Ann. Oncol. 21, 833-841 (2010).
85. Wang, Z. et al. Skp2: a novel potential therapeutic target for prostate cancer. Biochim. Biophys. Acta 1825, 11-17 (2012).
86. Li, J. Q. et al. Correlation of Skp2 with carcinogenesis, invasion, metastasis, and prognosis in colorectal tumors. Int. J. Oncol. 25, 87-95 (2004).
87. Rose, A. E. et al. Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell. Melanoma Res. 24, 197-206 (2011).
88. Fang, F. M. et al. Effect of S-phase kinase-Associated protein 2 expression on distant metastasis and survival in nasopharyngeal carcinoma patients. Int. J. Radiat. Oncol. Biol. Phys. 73, 202-207 (2009).
89. Schuler, S. et al. SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis. Int. J. Oncol. 38, 219-225 (2011).
90. Radke, S., Pirkmaier, A. & Germain, D. Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene 24, 3448-3458 (2005).
91. Zheng, W. Q., Zheng, J. M., Ma, R., Meng, F. F. & Ni, C. R. Relationship between levels of Skp2 and P27 in breast carcinomas and possible role of Skp2 as targeted therapy. Steroids 70, 770-774 (2005).
92. Lu, M. et al. The expression and prognosis of FOXO3a and Skp2 in human hepatocellular carcinoma. Pathol. Oncol. Res. 15, 679-687 (2009).
93. Ma, X. M., Liu, Y., Guo, J. W., Liu, J. H. & Zuo, L. F. Relation of overexpression of S phase kinase-Associated protein 2 with reduced expression of p27 and PTEN in human gastric carcinoma. World J. Gastroenterol. 11, 6716-6721 (2005).
94. Lee, H. et al. Mouse emi1 has an essential function in mitotic progression during early embryogenesis. Mol. Cell. Biol. 26, 5373-5381 (2006).
95. Lehman, N. L., Verschuren, E. W., Hsu, J. Y., Cherry, A. M. & Jackson, P. K. Overexpression of the anaphase promoting complex/cyclosome inhibitor Emi1 leads to tetraploidy and genomic instability of p53-deficient cells. Cell Cycle 5, 1569-1573 (2006).
96. Lehman, N. L. et al. Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors. Am. J. Pathol. 170, 1793-1805 (2007).
97. Gutgemann, I., Lehman, N. L., Jackson, P. K. & Longacre, T. A. Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod. Pathol. 21, 445-454 (2008).
98. Min, K. W. et al. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3. Int. J. Gynecol. Pathol. 32, 3-14 (2013).
99. Kip1. Hum. Pathol. 44, 365-373 (2013).
100. Cdh1. Nature Cell Biol. 4, 358-366 (2002).
101. Chen, J. Y., Wang, M. C. & Hung, W. C. Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells. J. Cell. Physiol. 226, 407-413 (2011).
102. Fernandez-Saiz, V. et al. SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. Nature Cell Biol. 15, 72-81 (2013).
103. Suzuki, T. et al. Mutation analyses of genes on 6p12-p11 in patients with juvenile myoclonic epilepsy. Neurosci. Lett. 405, 126-131 (2006).
104. Fuchs, S. Y., Spiegelman, V. S. & Kumar, K. G. The many faces of β-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 23, 2028-2036 (2004).
105. Nakayama, K. et al. Impaired degradation of inhibitory subunit of NF-κ B (I κ B) and β-catenin as a result of targeted disruption of the β-TrCP1 gene. Proc. Natl Acad. Sci. USA 100, 8752-8757 (2003).
106. Guardavaccaro, D. et al. Control of meiotic and mitotic progression by the F box protein β-Trcp1 in vivo. Dev. Cell 4, 799-812 (2003).
107. Kudo, Y. et al. Role of F-box protein βTrcp1 in mammary gland development and tumorigenesis. Mol. Cell. Biol. 24, 8184-8194 (2004).
108. Bhatia, N., Demmer, T. A., Sharma, A. K., Elcheva, I. & Spiegelman, V. S. Role of β-TrCP ubiquitin ligase receptor in UVB mediated responses in skin. Arch. Biochem. Biophys. 508, 178-184 (2011).
109. Ougolkov, A. et al. Associations among β-TrCP, an E3 ubiquitin ligase receptor, β-catenin, and NF-κB in colorectal cancer. J. Natl Cancer Institute 96, 1161-1170 (2004).
110. Muerkoster, S. et al. Increased expression of the E3-ubiquitin ligase receptor subunit βTRCP1 relates to constitutive nuclear factor-κB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res. 65, 1316-1324 (2005).
111. Koch, A. et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin. Cancer Res. 11, 4295-4304 (2005).
112. Kim, C. J. et al. Somatic mutations of the β-TrCP gene in gastric cancer. APMIS 115, 127-133 (2007).
113. Saitoh, T. & Katoh, M. Expression profiles of βTRCP1 and βTRCP2, and mutation analysis of βTRCP2 in gastric cancer. Int. J. Oncol. 18, 959-964 (2001).
114. Wu, X., Johansen, J. V. & Helin, K. Fbxl10/Kdm2b recruits polycomb repressive complex 1 to CpG islands and regulates H2A ubiquitylation. Mol. Cell 49, 1134-1146 (2013).
115. Tzatsos, A. et al. KDM2B promotes pancreatic cancer via Polycomb-dependent and-independent transcriptional programs. J. Clin. Invest. 123, 727-739 (2013).
116. Fukuda, T., Tokunaga, A., Sakamoto, R. & Yoshida, N. Fbxl10/Kdm2b deficiency accelerates neural progenitor cell death and leads to exencephaly. Mol. Cell. Neurosci. 46, 614-624 (2011).
117. He, J., Kallin, E. M., Tsukada, Y. & Zhang, Y. The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b). Nature Struct. Mol. Biol. 15, 1169-1175 (2008).
118. Frescas, D., Guardavaccaro, D., Bassermann, F., Koyama-Nasu, R. & Pagano, M. JHDM1B/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes. Nature 450, 309-313 (2007).
119. Fbxw4, interacts with the COP9 signalosome in an F-box dependent manner, is mutated, lost and under-expressed in human cancers. PLoS ONE 8, e63610 (2013).
120. Minoda, Y., Sakurai, H., Kobayashi, T., Yoshimura, A. & Takaesu, G. An F-box protein, FBXW5, negatively regulates TAK1 MAP3K in the IL-1β signaling pathway. Biochem. Biophys. Res. Commun. 381, 412-417 (2009).
121. Kanei-Ishii, C., Nomura, T., Egoh, A. & Ishii, S. Fbxw5 suppresses nuclear c-Myb activity via DDB1-Cul4-Rbx1 ligase-mediated sumoylation. Biochem. Biophys. Res. Commun. 426, 59-64 (2012).
122. Kim, T. Y. et al. CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-Activating protein tumor suppressor promotes non-small cell lung cancer cell growth. Proc. Natl Acad. Sci. USA 110, 16868-16873 (2013).
123. Hu, J. et al. WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase. Genes Dev. 22, 866-871 (2008).
124. De La Chesnaye, E. et al. Fbxw15/Fbxo12J is an F-box protein-encoding gene selectively expressed in oocytes of the mouse ovary. Biol. Reprod. 78, 714-725 (2008).
125. Fbxw15 mediates histone acetyltransferase binding to origin recognition complex (HBO1) ubiquitin-proteasomal degradation to regulate cell proliferation. J. Biol. Chem. 288, 6306-6316 (2013).
126. Chen, B. B. et al. F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation. Blood 119, 3132-3141 (2012).
127. Chen, B. B., Glasser, J. R., Coon, T. A. & Mallampalli, R. K. F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest. Oncogene 31, 2566-2579 (2012).
128. Chen, B. B., Glasser, J. R., Coon, T. A. & Mallampalli, R. K. Skp-cullin-F box E3 ligase component FBXL2 ubiquitinates Aurora B to inhibit tumorigenesis. Cell Death Dis. 4, e759 (2013).
129. Zhang, N. et al. FBXL5 interacts with p150Glued and regulates its ubiquitination. Biochem. Biophys. Res. Commun. 359, 34-39 (2007).
130. Ruiz, J. C., Walker, S. D., Anderson, S. A., Eisenstein, R. S. & Bruick, R. K. F-box and leucine-rich repeat protein 5 (FBXL5) is required for maintenance of cellular and systemic iron homeostasis. J. Biol. Chem. 288, 552-560 (2013).
131. Moroishi, T., Nishiyama, M., Takeda, Y., Iwai, K. & Nakayama, K. I. The FBXL5-IRP2 axis is integral to control of iron metabolism in vivo. Cell. Metab. 14, 339-351 (2011).
132. Zhu, J., Li, K., Dong, L. & Chen, Y. Role of FBXL20 in human colorectal adenocarcinoma. Oncol. Rep. 28, 2290-2298 (2012).
133. Eisfeld, A. K. et al. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood 120, 249-258 (2012).
134. Hirano, A. et al. FBXL21 regulates oscillation of the circadian clock through ubiquitination and stabilization of cryptochromes. Cell 152, 1106-1118 (2013)
135. Meziane el, K., Randle, S. J., Nelson, D. E., Lomonosov, M. & Laman, H. Knockdown of Fbxo7 reveals its regulatory role in proliferation and differentiation of haematopoietic precursor cells. J. Cell Sci. 124, 2175-2186 (2011).
136. Hsu, J. M., Lee, Y. C., Yu, C. T. & Huang, C. Y. Fbx7 functions in the SCF complex regulating Cdk1-cyclin B-phosphorylated hepatoma up-regulated protein (HURP) proteolysis by a proline-rich region. J. Biol. Chem. 279, 32592-32602 (2004).
137. Chang, Y. F., Cheng, C. M., Chang, L. K., Jong, Y. J. & Yuo, C. Y. The F-box protein Fbxo7 interacts with human inhibitor of apoptosis protein cIAP1 and promotes cIAP1 ubiquitination. Biochem. Biophys. Res. Commun. 342, 1022-1026 (2006).
138. Laman, H. et al. Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6. EMBO J. 24, 3104-3116 (2005).
139. Lomonosov, M. et al. Expression of Fbxo7 in haematopoietic progenitor cells cooperates with p53 loss to promote lymphomagenesis. PLoS ONE 6, e21165 (2011).
140. Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature 448, 313-317 (2007).
141. Valent, P. et al. Cancer stem cell definitions and terminology: the devil is in the details. Nature Rev. Cancer 12, 767-775 (2012).
142. Tokuzawa, Y. et al. Fbx15 is a novel target of Oct3/4 but is dispensable for embryonic stem cell self-renewal and mouse development. Mol. Cell. Biol. 23, 2699-2708 (2003).
143. FBXO28 ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol. Med. 5, 999-1018 (2013).
144. Bodine, S. C. et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704-1708 (2001).
145. Li, H. H. et al. Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J. Clin. Invest. 117, 3211-3223 (2007).
146. Tan, J. et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050-1063 (2007).
147. Chou, J. L. et al. Promoter hypermethylation of FBXO32, a novel TGF-β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab. Invest. 90, 414-425 (2010).
148. Song, M. H., Ha, J. C., Lee, S. M., Park, Y. M. & Lee, S. Y. Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX. Biochem. Biophys. Res. Commun. 408, 195-201 (2011).
149. Lu, Y. et al. The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation. J. Biol. Chem. 287, 41014-41022 (2012).
150. Peschiaroli, A., Scialpi, F., Bernassola, F., Pagano, M. & Melino, G. The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene 28, 3157-3166 (2009).
151. Saiga, T. et al. Fbxo45 forms a novel ubiquitin ligase complex and is required for neuronal development. Mol. Cell. Biol. 29, 3529-3543 (2009).
152. Chan, C. H. et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 154, 556-568 (2013).
153. Skp2 results in p27-And Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 111, 4690-4699 (2008).
154. Wu, L. et al. Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem. Biol. 19, 1515-1524 (2012).
155. Pavlides, S. C. et al. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer. Endocrinology 154, 4030-4045 (2013).
156. FBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471, 104-109 (2011).
157. Wertz, I. E. et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471, 110-114 (2011)
158. Min, S. H. et al. Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol. Cell 46, 771-783 (2012).
159. Wu, J. et al. Skp2 E3 ligase integrates ATM activation and homologous recombination repair by ubiquitinating NBS1. Mol. Cell 46, 351-361 (2012).
160. Miller, J. J. et al. Emi1 stably binds and inhibits the anaphase-promoting complex/cyclosome as a pseudosubstrate inhibitor. Genes Dev. 20, 2410-2420 (2006).
161. Nelson, D. E., Randle, S. J. & Laman, H. Beyond ubiquitination: the atypical functions of Fbxo7 and other F-box proteins. Open Biol. 3, 130131 (2013).
162. Reavie, L. et al. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell 23, 362-375 (2013).
163. Takeishi, S. et al. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 23, 347-361 (2013).
164. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157 (2011).
165. Le Gallo, M. et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nature Genet. 44, 1310-1315 (2012).
166. Huber, C. et al. Identification of mutations in CUL7 in 3-M syndrome. Nature Genet. 37, 1119-1124 (2005).
167. Chiaur, D. S. et al. Five human genes encoding F-box proteins: chromosome mapping and analysis in human tumors. Cytogenet. Cell Genet. 88, 255-258 (2000).
168. Laulier, C., Cheng, A., Huang, N. & Stark, J. M. Mammalian Fbh1 is important to restore normal mitotic progression following decatenation stress. DNA Repair (Amst.) 9, 708-717 (2010).
169. Signoretti, S. et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Invest. 110, 633-641 (2002).
170. Gstaiger, M. et al. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl Acad. Sci. USA 98, 5043-5048 (2001).
171. Yokoi, S. et al. Amplification and overexpression of SKP2 are associated with metastasis of non-small-cell lung cancers to lymph nodes. Am. J. Pathol. 165, 175-180 (2004).
172. Kanarek, N. et al. Spermatogenesis rescue in a mouse deficient for the ubiquitin ligase SCFβ-TrCP by single substrate depletion. Genes Dev. 24, 470-477 (2010).
173. Chen, S. et al. An insertion/deletion polymorphism in the 3' untranslated region of beta-transducin repeat-containing protein (βTrCP) is associated with susceptibility for hepatocellular carcinoma in Chinese. Biochem. Biophys. Res. Commun. 391, 552-556 (2010).
174. Scott, D. K. et al. Identification and analysis of tumor suppressor loci at chromosome 10q23.3-10q25.3 in medulloblastoma. Cell Cycle 5, 2381-2389 (2006).
175. Watanabe, T., Hikichi, Y., Willuweit, A., Shintani, Y. & Horiguchi, T. FBL2 regulates amyloid precursor protein (APP) metabolism by promoting ubiquitination-dependent APP degradation and inhibition of APP endocytosis. J. Neurosci. 32, 3352-3365 (2012).
176. Malard, V. et al. Global gene expression profiling in human lung cells exposed to cobalt. BMC Genomics 8, 147 (2007).
177. Takagi, H., Setou, M., Ito, S. & Yao, I. SCRAPPER regulates the thresholds of long-term potentiation/depression, the bidirectional synaptic plasticity in hippocampal CA3-CA1 synapses. Neural Plast. 2012, 352829 (2012).
178. Nelson, R. F. et al. Selective cochlear degeneration in mice lacking the F-box protein, Fbx2, a glycoprotein-specific ubiquitin ligase subunit. J. Neurosci. 27, 5163-5171 (2007).
179. Babaei-Jadidi, R. et al. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J. Exp. Med. 208, 295-312 (2011).
180. Davis, H. et al. FBXW7 mutations typically found in human cancers are distinct from null alleles and disrupt lung development. J. Pathol. 224, 180-189 (2011).
181. Jandke, A. et al. The F-box protein Fbw7 is required for cerebellar development. Dev. Biol. 358, 201-212 (2011).
182. Grim, J. E. et al. Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol. Cell. Biol. 32, 2160-2167 (2012).
183. Matsumoto, A. et al. Fbxw7-dependent degradation of Notch is required for control of "stemness" and neuronal-glial differentiation in neural stem cells. J. Biol. Chem. 286, 13754-13764 (2011).
184. Hoeck, J. D. et al. Fbw7 controls neural stem cell differentiation and progenitor apoptosis via Notch and c-Jun. Nature Neurosci. 13, 1365-1372 (2010).
185. Sancho, R. et al. Fbw7 repression by hes5 creates a feedback loop that modulates notch-mediated intestinal and neural stem cell fate decisions. PLoS Biol. 11, e1001586 (2013).
186. Kwon, Y. W. et al. Pten regulates Aurora-A and cooperates with Fbxw7 in modulating radiation-induced tumor development. Mol. Cancer Res. 10, 834-844 (2012).
187. Nakayama, K. et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J. 19, 2069-2081 (2000).
188. Zhong, L., Georgia, S., Tschen, S. I., Nakayama, K. & Bhushan, A. Essential role of Skp2-mediated p27 degradation in growth and adaptive expansion of pancreatic β cells. J. Clin. Invest. 117, 2869-2876 (2007).
189. Sakai, T. et al. Skp2 controls adipocyte proliferation during the development of obesity. J. Biol. Chem. 282, 2038-2046 (2007).
190. Fotovati, A., Nakayama, K. & Nakayama, K. I. Impaired germ cell development due to compromised cell cycle progression in Skp2-deficient mice. Cell Div. 1, 4 (2006).
191. Minamishima, Y. A. & Nakayama, K. Recovery of liver mass without proliferation of hepatocytes after partial hepatectomy in Skp2-deficient mice. Cancer Res. 62, 995-999 (2002).
192. Agarwal, A. et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood 112, 1960-1970 (2008).
193. Kratzat, S. et al. Cks1 is required for tumor cell proliferation but not sufficient to induce hematopoietic malignancies. PLoS ONE 7, e37433 (2012).
194. Kossatz, U. et al. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev. 18, 2602-2607 (2004).
195. Sistrunk, C., Macias, E., Nakayama, K., Kim, Y. & Rodriguez-Puebla, M. L. Skp2 is necessary for Myc-induced keratinocyte proliferation but dispensable for Myc oncogenic activity in the oral epithelium. Am. J. Pathol. 178, 2470-2477 (2011).
196. -/- mice. PLoS ONE 7, e36249 (2012).
197. Wang, J. et al. The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal. Blood 118, 5429-5438 (2011).
198. Baguma-Nibasheka, M. & Kablar, B. Abnormal retinal development in the Btrc null mouse. Dev. Dyn. 238, 2680-2687 (2009).